The nation’s top infectious disease expert, Anthony Fauci, MD, and other health officials are entering various levels of quarantine after potential exposure to coronavirus disease 2019 (COVID-19); the National Institute of Allergy and Infectious Diseases details how and why it halted a study on remdesivir in patients with COVID-19 early; the president’s economic advisers project rising unemployment rates.
After potential exposure to a White House staffer who tested positive for coronavirus disease 2019 (COVID-19), the nation’s top infectious disease expert, Anthony Fauci, MD, said he will begin a “modified quarantine” as he was not in close proximity with the person infected, while other top health officials, such as FDA Commissioner Stephen Hahn, MD, and CDC Director Robert Redfield, MD, will undergo full quarantines. As reported by CNN, Fauci will still testify at a Senate hearing about COVID-19 next week by wearing a mask. Conversely, Hahn and Redfield will now testify by video conference.
After halting its study 2 weeks ago examining the efficacy of Gilead Sciences’ antiviral drug remdesivir in patients with COVID-19, the National Institute of Allergy and Infectious Diseases (NIAID) discussed in a piece by STAT how it decided to stop the trial, which then limited researchers’ ability to collect more data on whether the drug saves lives. As indicated in the trial, the difference in mortality between patients with COVID-19 given remdesivir (8%) and placebo (11.6%) was not statistically significant when it was halted. However, officials at NIAID indicate that the potential of putting patients at risk of dying outweighed the need for proof of the drug’s efficacy.
Yesterday, 2 of President Donald Trump’s top economic advisers, Kevin Hassett and Treasury Secretary Steven Mnuchin, projected that the unemployment rate will continue to rise nationwide amid the pandemic, with Hassett predicting that it may reach 20% by next month. According to The Washington Post, Hassett said that it is unknown when those who lost their jobs will be able to return to work—a sentiment echoed by Mnuchin, who expects the second quarter of this year to be worse than the first. As of Friday, the US economy lost 20.5 million jobs in April.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More